Ardelyx reports $378 million in 2025 revenue, projects growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
January 8, 2026 8:30 AM ESTCompany achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1Â
IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241
IBSRELA expected to achieve $410-430 million in revenue in 2026
IBSRELA revenue expected to reach $1 billion in 2029
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided its preliminary... More
